The Immunohistochemistry Market size was estimated USD 2.4 billion in 2022 and is expected to reach USD 3.7 billion by 2030 at a CAGR of 5.9% during the forecast period of 2023-2030.
Immunohistochemistry is a microscopy technique for identifying antigens and macromolecular cellular components. It necessitates visualizing the presence and distribution of the target protein in diverse cell types, biological cycles, and even subcellular localization inside complex tissues.
.png)
The aging population will promote market revenue growth. The world's senior population is predicted to reach 1.6 billion by 2050, according to the United Nations (UN). As people age, cancer, cardiovascular disease, and neurological diseases become more common, demanding precise diagnosis and individualized care. The widespread application of immunohistochemistry techniques in the research and diagnosis of numerous diseases raises the demand for immunohistochemistry reagents and kits.
DRIVERS
Adoption of digital pathology boosting market growth
The growing trend of automation of diagnostic laboratory operations throughout major healthcare markets, digital pathology systems are increasingly being used by healthcare practitioners all over the world. Digital immunohistochemistry (IHC) combines traditional IHC staining with digital imaging and analysis tools, allowing stained tissue slides to be converted into electronic images that can be accessed, analyzed, and stored remotely, eliminating the need for physical slides and enabling efficient collaboration among pathologists and researchers. The benefits of digital pathology application in IHC are that it eliminates physical slide handling and storage, allows for remote collaboration among pathologists for case sharing and second opinions, enables objective and standardized quantitative analysis of staining, and allows for efficient archiving and integration of digital images with other data for comprehensive analysis and research.
RESTRAIN
Availability of Alternative Technologies
Immunohistochemistry is a popular technique in pathology for identifying proteins or antigens in tissue samples. There are other advanced technologies available for diagnostic and research reasons, some of them are as follows, RNA sequencing: RNA sequencing, also known as transcriptome sequencing, is a method for evaluating gene expression that is different from immunohistochemistry (HC). It entails figuring out the sequence and quantity of RNA molecules in the cell. Researchers can get data known as the transcriptome by sequencing the RNA, which provides insights into the activity of all genes within the cell. RNA sequencing enables a thorough examination of gene expression profiles without the limitations associated with immunohistochemistry.
OPPORTUNITY
Increasing significance of companion diagnostics
Companion diagnostics are tests or assays that help healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic goods has the potential to radically modify the drug development process and commercialize drug candidates by promptly and cost-effectively producing safer medications with better therapeutic efficacy. The market for companion diagnostics has a strong development potential due to an increase in demand for high-priced specialist therapies and safer medications. The increasing importance of companion diagnostics is also giving prospects for growth in the diagnostics segment, and in turn the immunohistochemistry market.
CHALLENGES
Stringent regulatory requirements
The present FDA approval process for tissue diagnostic equipment and consumables is time-consuming and complicated. This is a significant barrier for businesses when it comes to releasing new and creative products. Some tissue diagnostic products are classified as Class III (by the FDA) and require Premarket Approval (PMA) before they may be effectively sold. PMA is the most demanding marketing application, evaluating the safety and effectiveness of products.
In response to the ongoing conflict in Ukraine, Agilent Technologies, Inc. suspended sanctions-prohibited sales, halted product shipment to Russia with the exception of diagnostics and healthcare products, and limited our in-country service to those diagnostics and healthcare customers at the beginning of March. As a result, corporations discontinued substantial operations within Russia on May 23, 2022, and as a result, they recorded an inconsequential expense connected with the cessation of operations for the three months ended April 30, 2022. For the fiscal year ending October 31, 2022, sales from Russian clients comprised a negligible portion of our total revenue.
IMPACT OF ONGOING RECESSION
Despite navigating a challenging climate typified by supply chain and logistics pressures, high inflation, and a COVID-related closure in China in 2022, we were able to generate good results. In 2022, Agilent's net revenue of $6,848 million increased by 8% over the previous fiscal year. When compared to 2021, foreign currency changes had a 4% negative impact on sales growth in 2022. Net sales increased in all business categories, geographic regions, and the majority of key end markets. Revenue in the life sciences and applied markets business climbed by 9% in 2022. Foreign currency movements had a net negative impact on sales growth of 4% points in 2022. Diagnostics and genomics revenue increased by 7% in 2022.
By Product
Antibodies
Primary Antibodies
Secondary Antibodies
Equipment
Slide Staining System
Tissue Microarrays
Tissue Processing Systems
Slide Scanners
Others
Reagents
Histological stains
Blocking Sera & Reagents
Chromogenic Substrates
Fixation Reagents
Organic Solvents
Proteolytic Enzymes
Diluents
Other Reagents
Kits
In 2022, Antibodies segment is expected to held the highest market share of 41.1% during the forecast period due to the antibodies are so important in illness detection and drug testing. In terms of utilization rate, monoclonal antibodies and antibody-related goods such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominant product class. The antibodies are used in a variety of applications, including pathology, neuropathology, and hematopathology.
By Application
Diagnostics
Cancer
Infectious Diseases
Cardiovascular Diseases
Autoimmune Diseases
Diabetes Mellitus
Research
In 2022, the Diagnostics segment is expected to dominate the market growth of 69.2% during the forecast period. Immunohistochemistry (IHC) tests are commonly used to diagnose a variety of chronic disorders, including cancer, cardiovascular disease, infectious disease, diabetes mellitus, autoimmune diseases, and nephrological diseases. Furthermore, the rising prevalence of chronic disorders is expected to fuel the diagnostics segment.
By End User
Hospitals & Diagnostic Laboratories
Research Institutes
Others
.png)
In 2022, Pharmaceutical and Biotechnology Companies segment is expected to dominate the market growth of 57.6% during the forecast period owing to the serum-free medium is one of the key drivers of bio production, it can have a significant impact on viability and cell proliferation, as well as increase protein quality and production. Furthermore, the biopharmaceutical industry is expanding rapidly, not only as a result of the introduction of new therapies, but also as a result of the development of biosimilars or generics.
North America held a significant market share growing with a CAGR of 38.4% in 2022 due to the presence of key market participants, easy availability of IHC solutions, increasing use of technologically advanced IHC equipment, and introduction of newer IHC solutions. PathAI, a U.S.-based developer of AI-powered technology for pathological applications, for example, in June 2022, demonstrated a machine learning-based quality control tool built for HER2 testing in breast cancer at the American Society of Clinical Oncology virtual scientific program 2022.
Asia-Pacific is witness to expand fastest CAGR rate during the forecast period due to the expansion of the geographic footprint of the global players in the Asian markets. Furthermore, a large patient pool in countries such as India and China provides a large number of clinical subjects to carry out IHC R&D assays, resulting in revenue growth.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Danaher Corporation, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., Abcam plc., and Others.
Danaher Corporation (US), in April 2023, Danaher Corporation (US), through its subsidiary Leica Biosystems, has acquired FDA approval for the BOND MMR Antibody Panel for the diagnosis of colorectal cancer.
F. Hoffman-La Roche AG (Switzerland), in February 2023, F. Hoffman-La Roche AG (Switzerland) has introduced the IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody and the ATRX Rabbit Polyclonal Antibody for use in the BenchMark range of brain cancer detection instruments.
Agilent Technologies, Inc. (US), in January 2023, Agilent Technologies, Inc. (US) has entered into a collaboration agreement with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex tests. These assays will be utilized to develop diagnostic immunohistochemistry solutions.
| Report Attributes | Details |
| Market Size in 2022 | US$ 2.4 Billion |
| Market Size by 2030 | US$ 3.7 Billion |
| CAGR | CAGR of 5.9 % From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2019-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Antibodies, Equipment, Reagents, Kits) • By Application (Diagnostics, Research) • By End User (Hospitals & Diagnostic Laboratories, Research Institutes, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Danaher Corporation, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., Abcam plc. |
| Key Drivers | • Adoption of digital pathology boosting market growth |
| Market Opportunity | • Increasing significance of companion diagnostics |
Ans: Immunohistochemistry Market is anticipated to expand by 5.9% from 2023 to 2030.
Ans: USD 3.7 billion is expected to grow by 2030.
Ans: Immunohistochemistry Market size was valued at USD 2.4 billion in 2022.
Ans: Increasing demand for electronics devices and Increasing interest in power electronics
Ans: Rapid technological advancements in EMC Filtration.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Immunohistochemistry Market Segmentation, By Product
8.1 Antibodies
8.1.1 Primary Antibodies
8.1.2 Secondary Antibodies
8.2 Equipment
8.2.1 Slide Staining System
8.2.2 Tissue Microarrays
8.2.3 Tissue Processing Systems
8.2.4 Slide Scanners
8.2.5 Others
8.3 Reagents
8.3.1 Histological stains
8.3.2 Blocking Sera & Reagents
8.3.3 Chromogenic Substrates
8.3.4 Fixation Reagents
8.3.5 Organic Solvents
8.3.6 Proteolytic Enzymes
8.3.7 Diluents
8.3.8 Other Reagents
8.4 Kits
9. Immunohistochemistry Market Segmentation, By Application
9.1 Diagnostics
9.1.1Cancer
9.1.2Infectious Diseases
9.1.3Cardiovascular Diseases
9.1.4Autoimmune Diseases
9.1.5Diabetes Mellitus
9.1.6Nephrological Diseases
9.1.7Surface-Launched
9.1.8Underwater-Launched
9.2 Research
10. Immunohistochemistry Market Segmentation, By End User
10.1 Hospitals & Diagnostic Laboratories
10.2 Research Institutes
10.3 Others Conventional End User
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Immunohistochemistry Market by Country
11.2.2 North America Immunohistochemistry Market by Product
11.2.3 North America Immunohistochemistry Market by Application
11.2.4 North America Immunohistochemistry Market by End User
11.2.5 USA
11.2.5.1 USA Immunohistochemistry Market by Product
11.2.5.2 USA Immunohistochemistry Market by Application
11.2.5.3 USA Immunohistochemistry Market by End User
11.2.6 Canada
11.2.6.1 Canada Immunohistochemistry Market by Product
11.2.6.2 Canada Immunohistochemistry Market by Application
11.2.6.3 Canada Immunohistochemistry Market by End User
11.2.7 Mexico
11.2.7.1 Mexico Immunohistochemistry Market by Product
11.2.7.2 Mexico Immunohistochemistry Market by Application
11.2.7.3 Mexico Immunohistochemistry Market by End User
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Immunohistochemistry Market by Country
11.3.1.2 Eastern Europe Immunohistochemistry Market by Product
11.3.1.3 Eastern Europe Immunohistochemistry Market by Application
11.3.1.4 Eastern Europe Immunohistochemistry Market by End User
11.3.1.5 Poland
11.3.1.5.1 Poland Immunohistochemistry Market by Product
11.3.1.5.2 Poland Immunohistochemistry Market by Application
11.3.1.5.3 Poland Immunohistochemistry Market by End User
11.3.1.6 Romania
11.3.1.6.1 Romania Immunohistochemistry Market by Product
11.3.1.6.2 Romania Immunohistochemistry Market by Application
11.3.1.6.4 Romania Immunohistochemistry Market by End User
11.3.1.7 Turkey
11.3.1.7.1 Turkey Immunohistochemistry Market by Product
11.3.1.7.2 Turkey Immunohistochemistry Market by Application
11.3.1.7.3 Turkey Immunohistochemistry Market by End User
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Immunohistochemistry Market by Product
11.3.1.8.2 Rest of Eastern Europe Immunohistochemistry Market by Application
11.3.1.8.3 Rest of Eastern Europe Immunohistochemistry Market by End User
11.3.2 Western Europe
11.3.2.1 Western Europe Immunohistochemistry Market by Product
11.3.2.2 Western Europe Immunohistochemistry Market by Application
11.3.2.3 Western Europe Immunohistochemistry Market by End User
11.3.2.4 Germany
11.3.2.4.1 Germany Immunohistochemistry Market by Product
11.3.2.4.2 Germany Immunohistochemistry Market by Application
11.3.2.4.3 Germany Immunohistochemistry Market by End User
11.3.2.5 France
11.3.2.5.1 France Immunohistochemistry Market by Product
11.3.2.5.2 France Immunohistochemistry Market by Application
11.3.2.5.3 France Immunohistochemistry Market by End User
11.3.2.6 UK
11.3.2.6.1 UK Immunohistochemistry Market by Product
11.3.2.6.2 UK Immunohistochemistry Market by Application
11.3.2.6.3 UK Immunohistochemistry Market by End User
11.3.2.7 Italy
11.3.2.7.1 Italy Immunohistochemistry Market by Product
11.3.2.7.2 Italy Immunohistochemistry Market by Application
11.3.2.7.3 Italy Immunohistochemistry Market by End User
11.3.2.8 Spain
11.3.2.8.1 Spain Immunohistochemistry Market by Product
11.3.2.8.2 Spain Immunohistochemistry Market by Application
11.3.2.8.3 Spain Immunohistochemistry Market by End User
11.3.2.9 Netherlands
11.3.2.9.1 Netherlands Immunohistochemistry Market by Product
11.3.2.9.2 Netherlands Immunohistochemistry Market by Application
11.3.2.9.3 Netherlands Immunohistochemistry Market by End User
11.3.2.10 Switzerland
11.3.2.10.1 Switzerland Immunohistochemistry Market by Product
11.3.2.10.2 Switzerland Immunohistochemistry Market by Application
11.3.2.10.3 Switzerland Immunohistochemistry Market by End User
11.3.2.11.1 Austria
11.3.2.11.2 Austria Immunohistochemistry Market by Product
11.3.2.11.3 Austria Immunohistochemistry Market by Application
11.3.2.11.4 Austria Immunohistochemistry Market by End User
11.3.2.12 Rest of Western Europe
11.3.2.12.1 Rest of Western Europe Immunohistochemistry Market by Product
11.3.2.12.2 Rest of Western Europe Immunohistochemistry Market by Application
11.3.2.12.3 Rest of Western Europe Immunohistochemistry Market by End User
11.4 Asia-Pacific
11.4.1 Asia-Pacific Immunohistochemistry Market by Country
11.4.2 Asia-Pacific Immunohistochemistry Market by Product
11.4.3 Asia-Pacific Immunohistochemistry Market by Application
11.4.4 Asia-Pacific Immunohistochemistry Market by End User
11.4.5 China
11.4.5.1 China Immunohistochemistry Market by Product
11.4.5.2 China Immunohistochemistry Market by End User
11.4.5.3 China Immunohistochemistry Market by Application
11.4.6 India
11.4.6.1 India Immunohistochemistry Market by Product
11.4.6.2 India Immunohistochemistry Market by Application
11.4.6.3 India Immunohistochemistry Market by End User
11.4.7 Japan
11.4.7.1 Japan Immunohistochemistry Market by Product
11.4.7.2 Japan Immunohistochemistry Market by Application
11.4.7.3 Japan Immunohistochemistry Market by End User
11.4.8 South Korea
11.4.8.1 South Korea Immunohistochemistry Market by Product
11.4.8.2 South Korea Immunohistochemistry Market by Application
11.4.8.3 South Korea Immunohistochemistry Market by End User
11.4.9 Vietnam
11.4.9.1 Vietnam Immunohistochemistry Market by Product
11.4.9.2 Vietnam Immunohistochemistry Market by Application
11.4.9.3 Vietnam Immunohistochemistry Market by End User
11.4.10 Singapore
11.4.10.1 Singapore Immunohistochemistry Market by Product
11.4.10.2 Singapore Immunohistochemistry Market by Application
11.4.10.3 Singapore Immunohistochemistry Market by End User
11.4.11 Australia
11.4.11.1 Australia Immunohistochemistry Market by Product
11.4.11.2 Australia Immunohistochemistry Market by Application
11.4.11.3 Australia Immunohistochemistry Market by End User
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Immunohistochemistry Market by Product
11.4.12.2 Rest of Asia-Pacific Immunohistochemistry Market by Application
11.4.12.3 Rest of Asia-Pacific Immunohistochemistry Market by End User
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Immunohistochemistry Market by Country
11.5.1.2 Middle East Immunohistochemistry Market by Product
11.5.1.3 Middle East Immunohistochemistry Market by Application
11.5.1.4 Middle East Immunohistochemistry Market by End User
11.5.1.5 UAE
11.5.1.5.1 UAE Immunohistochemistry Market by Product
11.5.1.5.2 UAE Immunohistochemistry Market by Application
11.5.1.5.3 UAE Immunohistochemistry Market by End User
11.5.1.6 Egypt
11.5.1.6.1 Egypt Immunohistochemistry Market by Product
11.5.1.6.2 Egypt Immunohistochemistry Market by Application
11.5.1.6.3 Egypt Immunohistochemistry Market by End User
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Immunohistochemistry Market by Product
11.5.1.7.2 Saudi Arabia Immunohistochemistry Market by Application
11.5.1.7.3 Saudi Arabia Immunohistochemistry Market by End User
11.5.1.8 Qatar
11.5.1.8.1 Qatar Immunohistochemistry Market by Product
11.5.1.8.2 Qatar Immunohistochemistry Market by Application
11.5.1.8.3 Qatar Immunohistochemistry Market by End User
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Immunohistochemistry Market by Product
11.5.1.9.2 Rest of Middle East Immunohistochemistry Market by Application
11.5.1.9.3 Rest of Middle East Immunohistochemistry Market by End User
11.5.2 Africa
11.5.2.1 Africa Transfusion Diagnostics Market by Country
11.5.2.2 Africa Immunohistochemistry Market by Product
11.5.2.3 Africa Immunohistochemistry Market by Application
11.5.2.4 Africa Immunohistochemistry Market by End User
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Immunohistochemistry Market by Product
11.5.2.5.2 Nigeria Immunohistochemistry Market by Application
11.5.2.5.3 Nigeria Immunohistochemistry Market by End User
11.5.2.6 South Africa
11.5.2.6.1 South Africa Immunohistochemistry Market by Product
11.5.2.6.2 South Africa Immunohistochemistry Market by Application
11.5.2.6.3 South Africa Immunohistochemistry Market by End User
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Immunohistochemistry Market by Product
11.5.2.7.2 Rest of Africa Immunohistochemistry Market by Application
11.5.2.7.3 Rest of Africa Immunohistochemistry Market by End User
11.6 Latin America
11.6.1 Latin America Immunohistochemistry Market by Country
11.6.2 Latin America Immunohistochemistry Market by Product
11.6.3 Latin America Immunohistochemistry Market by Application
11.6.4 Latin America Immunohistochemistry Market by End User
11.6.5 Brazil
11.6.5.1 Brazil Immunohistochemistry Market by Product
11.6.5.2 Brazil Immunohistochemistry Market by Application
11.6.5.3 Brazil Immunohistochemistry Market by End User
11.6.6 Argentina
11.6.6.1 Argentina Immunohistochemistry Market by Product
11.6.6.2 Argentina Immunohistochemistry Market by Application
11.6.6.3 Argentina Immunohistochemistry Market by End User
11.6.7 Colombia
11.6.7.1 Colombia Immunohistochemistry Market by Product
11.6.7.2 Colombia Immunohistochemistry Market by Application
11.6.7.3 Colombia Immunohistochemistry Market by End User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Immunohistochemistry Market by Product
11.6.8.2 Rest of Latin America Immunohistochemistry Market by Application
11.6.8.3 Rest of Latin America Immunohistochemistry Market by End User
12. Company profile
12.1 Thermo Fisher Scientific Inc.
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 F. Hoffmann-La Roche Ltd.
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Merck KGaA
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Danaher Corporation
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Perkinelmer, Inc.
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Bio-Rad Laboratories, Inc.
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Cell Signaling Technology, Inc.
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Bio SB
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Agilent Technologies, Inc.
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Abcam plc.
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View
12.11 Others
13. Competitive Landscape
13.1 Competitive Bench marking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Medical Waste Containers Market Size was valued at USD 1.89 billion in 2022 and is expected to reach USD 3.02 billion by 2030, and grow at a CAGR of 6.0% over the forecast period 2023-2030.
The Host Cell Protein Testing Market Size was valued at USD 1.33 billion in 2023 and is expected to reach USD 2.11 billion by 2031 and grow at a CAGR of 5.93% over the forecast period 2024-2031.
The Ultrasound gels market size is projected to grow from $95.85 million in 2022 to $124.2 million by 2030, at a CAGR of 3.3% during the forecast period.
The Prepacked Chromatography Columns Market Size was valued at USD 2.73 billion in 2022, and is expected to reach USD 5.49 billion by 2030 and grow at a CAGR of 9.1% over the forecast period 2023-2030.
The Morphine Market Size was valued at USD 24.48 billion in 2022 and is expected to reach USD 45.31 billion by 2030 and grow at a CAGR of 8% over the forecast period 2023-2030.
The Life Science Tools Market size was estimated USD 145.01 billion in 2022 and is expected to reach USD 331.7 billion by 2030 at a CAGR of 10.9% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
